Navigation Links
MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
Date:3/14/2008

Presentation will be webcast live and archived on Company's web site

GERMANTOWN, Md., March 14 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that Dr. Edward M. Rudnic, MiddleBrook president and CEO, will deliver a corporate presentation on Tuesday, March 18, 2008, at 4:45 p.m. Eastern Time.

The presentation will take place as part of the Lehman Brothers Eleventh Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida. Dr. Rudnic's remarks will be available live on the MiddleBrook web site, where they also will be archived for 30 days.

To access the presentation, log on to http://www.middlebrookpharma.com and click on the Presentations option in the Investor Relations section. Please connect to the web site several minutes prior to the start of the live presentation to ensure adequate time for any software download that may be necessary.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded st
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Yuma Regional ... and complementary therapies brings comprehensive cancer care to ... Yuma Regional Cancer Center has officially opened. A ... program includes services such as open, semi-private and ... American Cancer Society Resource Center, hematology, rehabilitation center, ...
(Date:7/30/2014)... Md. , July 30, 2014 ... components to interrogate biology, but such devices can ... As such, researchers have looked ... in vitro metabolic engineering to characterize ... a chip. New devices are envisioned to recreate ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... San Diego, CA (PRWEB) July 30, 2014 ... second contract from the U.S. Environmental Protection Agency ... company’s expertise in developmental toxicity models, including tests ... on neuron formation and the formation of connections ... function. Inhibition of neurodifferentiation and synapse formation by ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... in Series of Global Distribution Agreements to Make ... Available to Researchers Everywhere--ZyGEM Also Announces Issuance of ... SOLANA BEACH, Calif. and HAMILTON, New Zealand ... Corp. Ltd. today announced that it has entered ...
... May 28 GenVec, Inc. (Nasdaq: GNVC ... with a single institutional investor for the sale of 9,615,385 shares ... its common stock. The shares of common stock and warrants ... stock and a warrant to purchase one share of common stock ...
... the Chinese Academy of Sciences in Beijing, scientists have ... to understand how they may help in the development ... , The research focused on rotating magnetic fields, which ... and generators. The difficulty for technology at the atomic ...
Cached Biology Technology:ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicon's Research and Diagnostic Products 2ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicon's Research and Diagnostic Products 3ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicon's Research and Diagnostic Products 4GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 3
(Date:7/30/2014)... baboons suggests that the route to a higher rank is ... of supportive sisters. , A female baboon,s social status is ... of her mother - the higher the mother is ranked, ... rank in female baboons is thought to be determined at ... spot in the pecking order, whereas females born to low-ranking ...
(Date:7/30/2014)... 30, 2014 NexID Biometrics , ... detection solutions for the biometric authentication industry, has ... revolutionizing online authentication with standards for strong authentication. ... "The decision to join FIDO Alliance stems from ... in use. We believe the FIDO Alliance is ...
(Date:7/30/2014)... through a massive collection of 20-million-year-old amber found in ... the effort is yielding fresh insights into ancient tropical ... collection is fully curated, a task that will take ... amber collection in the world, the researchers report. ... that of a pygmy locust, a tiny grasshopper the ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3NexID Biometrics Joins the FIDO Alliance 2Decades-old amber collection offers new views of a lost world 2
... salmon make one heck of a commute. The record holder in ... in the Clearwater River, Idaho, in April 2003. A year and ... near Japan. The most direct route between those two points ... Imagine fish that make it that far then turn around and ...
... reduces illness severity and duration in children one ... hours of symptom onset, according to new data ... Disease (WISPID) meeting in Bangkok 15-18 November. The ... incidence of respiratory tract infections, ear infections and ...
... as one-third of global energy consumption. However, unconventional changes ... emissions. ETH Zurich Professor for Sociology, Dirk Helbing, has ... could improve vehicular traffic flow by up to 95 ... ETH Zurich Chair of Sociology, a specialist in modelling ...
Cached Biology News:UW launches cutting-edge DNA 'fin-printing' project for salmon 2UW launches cutting-edge DNA 'fin-printing' project for salmon 3Tamiflu effective for treatment and prevention of influenza in children 1 year and older 2Tamiflu effective for treatment and prevention of influenza in children 1 year and older 3Traffic control systems 2Traffic control systems 3Traffic control systems 4
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
Request Info...
Request Info...
Candida (IgA) -Ab EIA Sample Size: 5 l...
Biology Products: